Business Case

Prioritization of tumor types for a tumor agnostic oncology asset to focus promotional efforts

Our clients, two large biopharma companies, partnered together to commercialize a biomarker-driven oncology drug with potential to receive a tumor-agnostic label. Given the broad number of potential tumor types that this drug could address, the clients needed to focus their promotional efforts. LSC helped to assess the potential for each of the tumor types, and group, prioritize, and gain alignment on the specific tumors to actively promote. Outcomes of this project helped to streamline field and omnichannel activities.